26 February 2025 - The approval marks the fifth regulatory approval of Andembry, reinforcing CSL’s decades long commitment to delivering innovative treatment modalities to the HAE community.

CSL announced today that the Swiss Agency for Therapeutic Products (Swissmedic) has granted marketing authorisation to Andembry (garadacimab) for long-term prophylaxis of recurring attacks of hereditary angioedema in adult and paediatric patients aged 12 years and older.

Read CSL press release